Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioForesight CEO Zhu Shen On Being A Matchmaker In China And Bridging Gaps Between East And West: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

BioForesight CEO Zhu Shen spoke to PharmAsia News along the sidelines of the recent Shanghai R&D Summit about managing relationships with CROs in China and opportunities being created there. San Diego-based BioForesight is a strategic consulting company providing partnering, investment and outsourcing advisory services as well as cross-cultural communication and negotiation training for clients in North America, Europe and China.

You may also be interested in...



BioForesight CEO Zhu Shen On Being A Matchmaker In China To Bridge Gaps Between East And West: An Interview With PharmAsia News (Part 2 of 2)

BioForesight CEO Zhu Shen spoke to PharmAsia News along the sidelines of the recent Shanghai R&D Summit about managing relationships with CROs in China and opportunities being created there. San Diego-based BioForesight is a strategic consulting company providing licensing, partnering and outsourcing advisory services as well as cross-cultural communication and negotiation training to clients in North America, Europe and China.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel